An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis

Vinodhini R. Mudaliyar; Asha Pathak; Alok Dixit; Sweta  Kumar

doi:10.5826/dpc.1004a94

An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis

Authors

Vinodhini R. Mudaliyar Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, India
Asha Pathak Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, India
Alok Dixit Department of Pharmacology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, India
Sweta Kumar Department of Dermatology, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, India

Keywords:

topical corticosteroids, topical calcineurin inhibitors, fluticasone propionate, tacrolimus, atopic dermatitis

Abstract

Background: Atopic dermatitis (AD), a chronic recurrent inflammatory skin condition primarily affects children. Topical treatment, systemic treatment, and phototherapy are mainstay of treatment.

Objectives: Topical corticosteroids (TCS) are the first line therapy for AD but are associated with various adverse effects. Topical calcineurin inhibitor (TCI) can be used as an alternative to TCS. The aim of the study is to compare efficacy of topical preparation of fluticasone and tacrolimus in lowering the severity of disease, to assess the quality of life (QoL), and to estimate if any association exists between them.

Methods: 37 AD children, randomly received either of the two topical treatments, daily application for first 4 week of in acute phase and twice weekly for next 4 week as maintenance phase. The severity of disease was assessed using SCORing Atopic Dermatitis (SCORAD) and QoL was assessed by using Children’s Dermatology Life Quality Index (CDLQI).

Results: At the end of acute phase, there was reduction in SCORAD score by 69.29% in fluticasone and 64.20% in tacrolimus group (P<0.001). In maintenance phase, the score had risen in fluticasone group by a mean difference of 0.81 while in tacrolimus, it decreased by 0.99. Both fluticasone and tacrolimus groups improved children’s QoL (P<0.001). Positive correlation (r=0.4668) exists between the SCORAD and QoL. Skin burning was the most common ADR seen with tacrolimus.

Conclusions: Fluticasone and tacrolimus are equally efficacious in the treatment of AD, with similar benefits on children’s QoL. Tacrolimus is better in reducing the extent of lesions than fluticasone

References

Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic dermatitis in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 pt 1):125-138. DOI: 10.1016/S0091-6749(99)70536-1.

Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159-162. DOI: 10.1136/adc.76.2.159.

Filanovsky MG, Pootongkam S, Tamburro JE, Smith MC, Ganocy SJ, Nedorost ST. The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr. 2016;169:285-290. DOI: 10.1016/j.jpeds.2015.10.077.

Rajagopalan M, De A, Godse K, et al. Guidelines on management of atopic dermatitis in India: an evidence-based review and an expert consensus. Indian J Dermatol. 2019;64(3):166-181. DOI: 10.4103/ijd.IJD_683_18.

Ahluwalia A. Topical glucocorticoids and the skin—mechanisms of action: an update. Mediators Inflamm. 1998;7(3):183-193. DOI: 10.1080/09629359891126.

Altura BM. Role of Glucocorticoids in local regulation of blood flow. Am J Physiol. 1966;211(6):1393-1397. DOI: 10.1152/ajplegacy.1966.211.6.1393.

Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. DOI: 10.1016/j.jaad.2014.03.023.

Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacological effects. Allergy Asthma Proc. 2002;23(3):191-197. PMID: 12125507.

Billiach A, Aschauer H, Aszodi A, Steutz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269(1):29-35. DOI: 10.1016/j.ijpharm.2003.07.013.

Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326(7403):1367. DOI: 10.1136/bmj.326.7403.1367. DOI: 10.1136/bmj.326.7403.1367.

Breneman D, Fleischer AB, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease controlled in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58(6):990-999. DOI: 10.1016/j.jaad.2008.02.008.

Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener (Stockholm). 1980;92:44-47.

Finlay AY, Williams AY, Harding KG. "Fingertip unit" in dermatology. Lancet. 1989;2:155. DOI: 10.1016/S0140-6736(89)90204-3.

Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI: 10.1159/000245677.

Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949. DOI: 10.1111/j.1365-2133.1995.tb16953.x.

Sarkar R, Kanwar AJ. Clinico-epidemiological profile and factors affecting severity of atopic dermatitis in north Indian children. Indian J Dermatol. 2004;49(3):117-122.

Sampson HA. Atopic dermatitis. In: Feigin RD, Oski FA, DeAngelis C, eds. Oski's Pediatrics Principles & Practice. 4th ed. Lippincott Williams & Wilkins; 2006:2423-2424.

Takeuchi S, Saeki H, Tokunaga S, et al. A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritus in patients with atopic dermatitis. Ann Dermatol. 2012;24(2):144-150. DOI: 10.5021/ad.2012.24.2.144

Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy. 2004;34(4):639-645. DOI: 10.1111/j.1365-2222.2004.1907.x

Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized double-blind, non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol. 2010;21(2 pt 1):321-329. DOI: 10.1111/j.1399-3038.2009.00895.x.

Kim DH, Li K, Seo SJ, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. J Korean Med Sci. 2012;27(11):1327-1332. DOI: 10.3346/jkms.2012.27.11.1327

Bezerra Campos AL, Moreira de Araujo F, Lopes dos Santos MA, de Assis Santos dos Santos A, Avelar Pires CA. Impact of atopic dermatitis on the quality of life of pediatric patients and their guardians. Rev Paul Pediatr. 2017;35(1):5-10. DOI: 10.1590/1984-0462/;2017;35;1;00006.

Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1 Suppl):S47-S57. DOI: 10.1067/mjd.2001.109813.